ECSP20007842A - Composiciones y métodos para formulaciones de alfavirus vivos atenuados - Google Patents

Composiciones y métodos para formulaciones de alfavirus vivos atenuados

Info

Publication number
ECSP20007842A
ECSP20007842A ECSENADI20207842A ECDI202007842A ECSP20007842A EC SP20007842 A ECSP20007842 A EC SP20007842A EC SENADI20207842 A ECSENADI20207842 A EC SENADI20207842A EC DI202007842 A ECDI202007842 A EC DI202007842A EC SP20007842 A ECSP20007842 A EC SP20007842A
Authority
EC
Ecuador
Prior art keywords
live attenuated
compositions
methods
alfavirus
formulations
Prior art date
Application number
ECSENADI20207842A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill Ann Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP20007842(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of ECSP20007842A publication Critical patent/ECSP20007842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las modalidades en este documento se refieren a composiciones de y métodos para alfavirus vivos atenuados. En ciertas modalidades, una composición de virus vivo atenuado incluye, pero no se limita a, uno o más alfavirus vivos atenuados y composiciones para reducir la inactivación y/o degradación del alfavirus vivo atenuado. En otras modalidades, la composición de virus vivo atenuado puede ser una composición de vacuna. En otras composiciones, una composición de alfavirus vivo atenuado puede incluir tampón de HEPES. En otras modalidades, el tampón de HEPES puede incluir además un carbohidrato y gelatina y/o una sal.
ECSENADI20207842A 2013-03-14 2020-01-31 Composiciones y métodos para formulaciones de alfavirus vivos atenuados ECSP20007842A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
ECSP20007842A true ECSP20007842A (es) 2020-09-30

Family

ID=50489420

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20207842A ECSP20007842A (es) 2013-03-14 2020-01-31 Composiciones y métodos para formulaciones de alfavirus vivos atenuados

Country Status (19)

Country Link
US (2) US10137186B2 (es)
EP (2) EP2968515B1 (es)
JP (3) JP6426695B2 (es)
KR (1) KR20160003662A (es)
CN (2) CN111729077A (es)
AP (1) AP2015008733A0 (es)
AU (2) AU2014236804B2 (es)
BR (1) BR112015023205A2 (es)
CA (1) CA2903711A1 (es)
CR (1) CR20150553A (es)
DO (1) DOP2015000226A (es)
EC (1) ECSP20007842A (es)
MX (2) MX361342B (es)
MY (1) MY178476A (es)
NZ (1) NZ631012A (es)
PH (1) PH12015502115B1 (es)
SG (3) SG11201507462QA (es)
TW (2) TWI649087B (es)
WO (1) WO2014151855A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968515B1 (en) * 2013-03-14 2019-05-08 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
SG11201808458QA (en) * 2016-03-31 2018-10-30 Takeda Vaccines Inc Compositions and methods for stabilizing alphaviruses with improved formulations
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
CN115836123B (zh) * 2021-01-19 2024-12-31 新田明胶株式会社 病毒稳定剂、病毒稳定剂用明胶水解物以及含病毒的组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6465634B1 (en) * 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
WO2000011201A1 (en) * 1998-07-30 2000-03-02 Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
JP4550421B2 (ja) * 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
WO2005058356A2 (en) 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
AU2007317847B2 (en) 2006-11-07 2013-10-31 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
PT2144998T (pt) 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados
ES2566527T3 (es) 2007-09-04 2016-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Inactivación térmica de rotavirus
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
JP5758632B2 (ja) 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用
MY160201A (en) * 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20130243841A1 (en) * 2010-06-01 2013-09-19 Novartis Ag Concentration of vaccine antigens with lyophilization
EP2968515B1 (en) 2013-03-14 2019-05-08 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
CN105377293B (zh) 2020-07-17
US20140271715A1 (en) 2014-09-18
AP2015008733A0 (en) 2015-09-30
TW201513875A (zh) 2015-04-16
EP2968515B1 (en) 2019-05-08
JP6426695B2 (ja) 2018-11-21
JP2020193231A (ja) 2020-12-03
AU2014236804A1 (en) 2015-10-01
SG10201909051QA (en) 2019-11-28
KR20160003662A (ko) 2016-01-11
US10137186B2 (en) 2018-11-27
JP2016513658A (ja) 2016-05-16
EP3603667A1 (en) 2020-02-05
AU2018236897B2 (en) 2020-09-10
MX361342B (es) 2018-12-04
PH12015502115B1 (en) 2019-08-09
AU2014236804B2 (en) 2018-12-13
CN105377293A (zh) 2016-03-02
CA2903711A1 (en) 2014-09-25
WO2014151855A1 (en) 2014-09-25
JP2019031543A (ja) 2019-02-28
MY178476A (en) 2020-10-14
TWI649087B (zh) 2019-02-01
US10806781B2 (en) 2020-10-20
MX2015012894A (es) 2016-04-04
NZ631012A (en) 2017-08-25
JP6761015B2 (ja) 2020-09-23
AU2018236897A1 (en) 2018-10-18
SG10201801459SA (en) 2018-03-28
DOP2015000226A (es) 2016-02-29
BR112015023205A2 (pt) 2017-07-18
CR20150553A (es) 2015-12-01
PH12015502115A1 (en) 2016-01-25
MX2018014977A (es) 2022-06-27
EP2968515A1 (en) 2016-01-20
CN111729077A (zh) 2020-10-02
TW201900192A (zh) 2019-01-01
US20190134182A1 (en) 2019-05-09
SG11201507462QA (en) 2015-10-29
HK1220358A1 (en) 2017-05-05

Similar Documents

Publication Publication Date Title
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CL2016001547A1 (es) Composiciones para el cuidado oral
CO2019001448A2 (es) Composiciones y métodos para estabilizar flavivirus con formulaciones mejoradas
MX2016012938A (es) Composiciones estables de yodo no en complejo y metodos de uso.
EA201591761A1 (ru) Композиции на основе наночастиц
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
MX2016006060A (es) Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX368954B (es) Insectos modificados para reducir la expresion genica especifica en los testiculos para los metodos de control biologico.
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
DOP2018000209A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CR20130610A (es) Método de tratamiento de la fiebre dengue
EA201790415A1 (ru) ЛИОФИЛИЗИРОВАННЫЕ СОСТАВЫ ДЛЯ АНТИДОТА ФАКТОРА Xa
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO2018010357A2 (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
UY35390A (es) Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
CL2020000586A1 (es) Moduladores de la expresión de enac.